---
title: "Funding of science"
chunk: 4/5
source: "https://en.wikipedia.org/wiki/Funding_of_science"
category: "reference"
tags: "science, encyclopedia"
date_saved: "2026-05-05T03:24:31.702550+00:00"
instance: "kb-cron"
---

Disclosure of potential conflicts of interest (COIs) is used by journals to guarantee credibility and transparency of the scientific process. Conflict of interest disclosure, however, is not systematically nor consistently dealt with by journals that publish scientific research results.
When research is funded by the same agency that can be expected to gain from a favorable outcome there is a potential for biased results and research shows that results are indeed more favorable than would be expected from a more objective view of the evidence. A 2003 systematic review studied the scope and impact of industry sponsorship in biomedical research. The researchers found financial relationships among industry, scientific investigators, and academic institutions widespread. Results showed a statistically significant association between industry sponsorship and pro-industry conclusions and concluded that "Conflicts of interest arising from these ties can influence biomedical research in important ways." A British study found that a majority of the members on national and food policy committees receive funding from food companies.
In an effort to cut costs, the pharmaceutical industry has turned to the use of private, nonacademic research groups (i.e., contract research organizations [CROs]) which can do the work for less money than academic investigators.  In 2001 CROs came under criticism when the editors of 12 major scientific journals issued a joint editorial, published in each journal, on the control over clinical trials exerted by sponsors, particularly targeting the use of contracts which allow sponsors to review the studies prior to publication and withhold publication of any studies in which their product did poorly. They further criticized the trial methodology stating that researchers are frequently restricted from contributing to the trial design, accessing the raw data, and interpreting the results.
The Cochrane Collaboration, a worldwide group that aims to provide compiled scientific evidence to aid well informed health care decisions,  conducts systematic reviews of randomized controlled trials of health care interventions and tries to disseminate the results and conclusions derived from them.  A few more recent reviews have also studied the results of non-randomized, observational studies. The systematic reviews are published in the Cochrane Library. A 2011 study done to disclose possible conflicts of interests in underlying research studies used for medical meta-analyses reviewed 29 meta-analyses and found that conflicts of interest in the studies underlying the meta-analyses were rarely disclosed.  The 29 meta-analyses reviewed an aggregate of 509 randomized controlled trials. Of these, 318 trials reported funding sources with 219 (69%) industry funded. 132 of the 509 trials reported author disclosures of conflict of interest, with 91 studies (69%) disclosing industry financial ties with one or more authors. However, the information was seldom reflected in the meta-analyses. Only two (7%) reported funding sources and none reported author-industry ties. The authors concluded, "without acknowledgment of COI due to industry funding or author industry financial ties from RCTs included in meta-analyses, readers' understanding and appraisal of the evidence from the meta-analysis may be compromised."
In 2003 researchers looked at the association between authors' published positions on the safety and efficacy in assisting with weight loss of olestra, a fat substitute manufactured by the Procter & Gamble (P&G), and their financial relationships with the food and beverage industry.  They found that supportive authors were significantly more likely than critical or neutral authors to have financial relationships with P&G and all authors disclosing an affiliation with P&G were supportive. The authors of the study concluded: "Because authors' published opinions were associated with their financial relationships, obtaining noncommercial funding may be more essential to maintaining objectivity than disclosing personal financial interests."
A 2005 study in the journal Nature surveyed 3247 US researchers who were all publicly funded (by the National Institutes of Health). Out of the scientists questioned, 15.5% admitted to altering design, methodology or results of their studies due to pressure of an external funding source.

=== Regulatory capture ===
Private funding may also be channeled to public funders. In 2022, a news story broke following the resignation of Eric Lander, former director of the Office of Science and Technology Policy (OSTP) in the Biden administration, that the charity of former Google executive Eric Schmidt, Schmidt Futures, paid salaries of numerous OSTP employees. Eventually, ethics inquiries were initiated in the OSTP.

=== Efficiency of funding ===

The traditional measurement for efficiency of funding are publication output, citation impact, number of patents, number of PhDs awarded etc. However, the use of journal impact factor has generated a publish-or-perish culture and a theoretical model has been established whose simulations imply that peer review and over-competitive research funding foster mainstream opinion to monopoly. Calls have been made to reform research assessment, most notably in the San Francisco Declaration on Research Assessment and the Leiden Manifesto for research metrics. The current system also has limitations to measure excellence in the Global South. Novel measurement systems such as the Research Quality Plus has been put forward to better emphasize local knowledge and contextualization in the evaluation of excellence. A wide range of interventions has been proposed to improve science funding. Open peer review can improve the quality of scholarly peer review. A systematic review found a scarcity of randomized controlled trials on peer review interventions.
Another question is how to allocate funds to different disciplines, institutions, or researchers. A recent study by Wayne Walsh found that "prestigious institutions had on average 65% higher grant application success rates and 50% larger award sizes, whereas less-prestigious institutions produced 65% more publications and had a 35% higher citation impact per dollar of funding."

== Trends ==

In endogenous growth theory, R&D investments contribute to the country's increase in economic growth. Therefore, countries have strong incentives to maintain R&D investments.